Bright Spot: The Biophotonics Center Shines Light on the Intersection of Physics, Engineering and Medicine

Tucked away on a service road between the edge of Vanderbilt’s main campus and Vanderbilt University Medical Center sits a brick building so intentionally nondescript, other than its tall façade of darkened glass, that it practically screams “mystery” to casual passersby. The intrigue only deepens as you read the sign outside: “W.M. Keck Free Electron Laser (FEL) Center.”

Despite the foreboding exterior, inside is a state-of-the-art laser laboratory that serves as a kind of hub of cross-disciplinary research at Vanderbilt. Forty faculty members from across the university and VUMC—working on topics ranging from astrophysics to cancer treatments—have an affiliation with what is now known as the Biophotonics Center. Led by Anita Mahadevan-Jansen, the Orrin H. Ingram Professor of Biomedical Engineering and professor of neurological surgery, the center also provides undergraduate and graduate students with hands-on experience at one of the world’s leading optics facilities.

The center’s origins trace back to a U.S. Department of Defense grant from the 1980s exploring the use of lasers to treat combat wounds. Then, as now, the center offered an ideal location for such work, situated midway between physics and engineering research labs on one side and patient rooms at VUMC on the other. Similar government-funded facilities were built around the same time at Stanford, Duke, Harvard, and the University of California–Irvine. However, military funding for the program ended in 2007, and Vanderbilt’s Free Electron Laser center closed a year later as a result.

Then last February, the 5,000-square-foot center officially reopened after an extensive renovation. Ongoing research there covers three main areas: cancer treatment and detection, neurosurgery, and nanotechnology. “The Biophotonics Center is aimed at fundamental research and discovery, as well as improving patient care,” Mahadevan-Jansen says. Current funding for biophotonics research at Vanderbilt totals nearly $25 million.

In this photo essay, Vanderbilt Magazine takes a peek inside the Biophotonics Center and some of the work now being done based on research there.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Red light can reduce blood glucose levels

The researchers found that 670 nm red light stimulated energy production within mitochondria, the tiny powerhouses within cells, leading to increased consumption of glucose. In particular, it led to a 27.7% reduction in blood glucose levels following glucose intake, and it reduced maximum glucose spiking by 7.5%.

While the study was conducted in healthy individuals, the non-invasive, non-pharmacological technique has the potential to have an impact on diabetes control after meals, as it can reduce damaging fluctuations of blood glucose in the body that contribute to ageing.

The study also highlights the significant long-term consequences for human health, including the potential dysregulation of blood sugars posed by lengthy exposure to blue light. Given the prominence of LED lighting in modern technology and environments, and the fact that LEDs emit towards the blue end of the spectrum with very little red, the authors suggest that this may be a potential public health issue. The research has been published in the Journal of Biophotonics.

Mitochondria provide energy for vital cellular processes, using oxygen and glucose to produce the energy-rich nucleoside adenosine triphosphate (ATP). Previous research has established that long wavelength light between approximately 650-900 nm (spanning the visible through to the near-infrared range) can increase mitochondrial production of ATP which reduces blood glucose and also improves health/lifespan in animals. 

The authors Dr Michael Powner, Senior Lecturer in Neurobiology in the School of Health and Psychological Sciences at City, and Professor Glen Jeffery, Professor of Neuroscience in the UCL Institute of Ophthalmology, also say that this improvement in ATP production can cause signalling changes that are transmitted throughout the body.

They suggest that it may be mediating the abscopal effect, which refers to the phenomenon in cancer treatment where specific irradiation of a primary tumour can result in shrinkage of secondary tumours located in a different part of the body. Likewise, 670 nm light shone selectively on to the backs of mice in previous studies has been shown to result in improvements in ATP that improve symptoms in both a model of Parkinson’s disease and a model of diabetic retinopathy.

To explore the impact of 670 nm red light on blood glucose, the researchers recruited 30 healthy participants, who were then randomised into two groups: 15 in the 670 nm red light group, and 15 in the placebo (no light) group. They had no known metabolic conditions (such as diabetes) and were not taking medication.

Participants were then asked to do an oral glucose tolerance test (drinking glucose dissolved in water) and record their blood glucose levels every 15 minutes over the next two hours. People who received red light exposure 45 minutes prior to drinking glucose exhibited a reduced peak blood glucose level and reduced total blood glucose during the two hours.

Dr Powner, who was the lead author of the study, said: “It is clear that light affects the way mitochondria function and this impacts our bodies at a cellular and physiological level. Our study has shown that we can use a single, 15-minute exposure to red light to reduce blood sugar levels after eating.

“While this has only been done in healthy individuals in this paper, it has the potential to impact diabetes control going forward, as it could help to reduce potentially damaging glucose spikes in the body after meals.”

Professor Jeffery said: “Sunlight has a balance between red and blue, but we now live in a world where blue light is dominant because although we do not see it, LED lights are dominant in blue and have almost no red in them. This reduces mitochondrial function and ATP production. Hence our internal environments are red-starved. Long-term exposure to blue light is potentially toxic without red. Blue light on its own impacts badly on physiology and can drive disrupted blood sugars that may in the long run contribute to diabetes and undermine health spans.

“Pre-1990, we all had incandescent lighting which was OK because it had the balance of blue and red similar to sunlight, but there is a potential health span time bomb in the change to LEDs in an ageing population. This can partly be corrected by spending more time in sunlight.”


World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Biophotonics Market Size & Share Report, 2025 - 2034

 Biophotonics Market Size

The global biophotonics market size was valued at USD 76.1 billion in 2024 and is estimated to grow at CAGR of 11.3% to reach USD 220.1 billion by 2034. Rising technological innovation in the medical sector coupled with the rapid emergence of nanotechnology are the major factors contributing to the growth of the market.

As nanotechnology enables unprecedented control over light-matter interactions at the nanoscale, which helps in improving the performance of diagnostic and therapeutic tools its rapid emergence is the key factor driving the biophotonic market. For instance, according to GMI analysis the global nanotechnology in medical devices market size was valued at USD 4.7 billion in 2024 and is expected grow at a CAGR of 9.2% from 2025 to 2034. By employing nanomaterials including metallic nanoparticles and quantum dots, biophotonic devices enable higher sensitivity and specificity for sensing biomarkers as well as for tissue imaging. All this is resulting in detection at earlier disease stages and also with more specific treatments.

The global aging demographic is creating a significant opportunity for the biophotonics market. As per the WHO data world's population over 60 years will double from 12% to 22% between 2015-2050. Moreover, according to WHO  1 in 6 people in the world will be aged 60 years or over by 2030. As aging consumers become more in need of advanced diagnostic and monitoring products, companies stand to meet a rising demand for non-invasive, high-accuracy healthcare products. By targeting age-related diseases like cancer and cardiovascular disease, companies can benefit from a strong market segment that requires ongoing innovation and enhanced patient care.
Lifestyle diseases, including diabetes, obesity, and cardiovascular disorders, are on the rise, creating a substantial market push for advanced biophotonic solutions. For instance, according to WHO Diabetes and kidney disease caused over 2 million deaths and around 11% of cardiovascular deaths were caused by high blood glucose in 2021. These conditions call for proactive management by early diagnosis and routine monitoring services that biophotonic technologies are capable of providing.

Manufacturers should incorporate nanotechnology into biophotonic devices to increase diagnostic accuracy and therapeutic efficacy, in order to meeting the growing needs for cutting-edge medical technologies. Moreover, they should focus on developing technologies which facilitate early detection and monitoring of lifestyle diseases, such as diabetes and obesity, to tap rising market segments.

Biophotonics Market Trends

• Integration of artificial intelligence (AI) and machine learning (ML) in biophotonics industry is on the rise. These technologies helps in optimizing processes related to imaging data interpretation which enables quicker and more reliable diagnoses. AI-driven biophotonics techniques such as Raman spectroscopy integrated with machine learning have shown great success in the recent studies. For example, in 2024, University of Edinburgh researchers were able to detect early breast cancer with a 98% accuracy. This system identified tiny chemical changes present in blood tests that other methods fail to consider.
   
• The biophotonics sector is noticing transformative advancements, particularly with the development of non-invasive imaging techniques that significantly enhance both life science research and patient care. A prime example is the advent of near-infrared II (NIR-II) fluorescence imaging, which offers deeper tissue penetration and higher resolution compared to earlier imaging modalities. This technology has become instrumental in cancer surgeries by facilitating precise tumour localization and delineation of tumour margins, thereby improving surgical accuracy and patient outcomes. Apart from oncology, NIR-II fluorescence imaging broadens the scope of its application in various fields of medicine such as enhancing anatomical mapping and complex biological structure visualization. The incorporation of NIR-II fluorescence imaging into clinical practice highlights the need for advancing biophotonic technologies, which offers abundant prospects for healthcare innovation and investment.
   
• Biophotonics industry is also aided by a rise in strategic partnerships and research expenditure within industry, academia, and government laboratories. For example, in November 2023, at the Society for Neuroscience (SfN) annual meeting, ZEISS Group revealed cutting-edge imaging technology that encompasses next-generation fluorescence microscopy methods These technologies allow scientists to visualize cellular structures and processes at higher clarity and precision than ever before. Some of these innovations are improved resolution capability and increased imaging speed, which are essential to image dynamic biological processes in real time. Such collaborations are instrumental in driving technological advancement and shortening time-to-market for emerging diagnostic technology. Joint collaborations are helping bring together resources, reduce expenses, and reducing the risks involved with new product creation. This is not only leading to ongoing innovation in biophotonic technology but enhancing overall firm competitiveness for companies that are operating within this dynamic marketplace.
   Based on technology, the market is divided into In-Vitro and In-Vivo.

   

  • The In-Vitro market is growing at the significant rate and is expected to reach the market size of USD 89.6 billion in 2034. Advancements in diagnostic and analytical technologies is the major factor responsible for growth in the segment. Integration of automation and AI-based analysis in in-vitro platforms enables to streamline workflows, reduced error rates, and optimized laboratory operations which is the major factor contributing to the segment growth. Moreover, increasing demand for early disease detection and personalized medicine is also expected to boost the market.
     
  • The In-Vivo market held the largest share of 57 % in the year 2024 and is expected to continue its domination till the forecast period. Technological advancements, especially in the field of optical imaging and laser diagnostics, have greatly enhanced the accuracy and safety of such treatments. This has resulted in higher clinical uptake for uses like cancer detection at early stages, supported surgeries, and tracking of physiological processes which is driving the market.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Optical Filter Orientation Dictates System Effectiveness

When integrating an optical filter into the design of an optical system, it is vital to understand the angle of incidence (AOI) and cone half angle (CHA) requirements on the filters to optimize functionality for a wide variety of life sciences and biomedical research applications. The larger the deviation from the designed AOI, the greater the peak wavelength shift and the overall transmission drop.

Increasing the AOI blue shifts the transmission peak toward shorter wavelengths, while reducing the AOI red shifts the transmission peak toward longer wavelengths. In wavelength-dependent application spaces, such as fluorescence spectroscopy and nuclear magnetic resonance, a misaligned filter with too much red/blue shift would be severely detrimental to experimental results or device readings.

The larger the CHA of the incoming light, the greater the loss in peak transmission and the greater the peak broadening, which can allow unwanted wavelengths adjacent to the design wavelength to pass through the filter.

Certain design techniques can be implemented by system developers to decrease a filter’s sensitivity to the effects of AOI and CHA. This article discusses the importance of considering angular effects on filter performance in optical system design, as well as potential mitigation strategies.

Impact of angle of incidence

The AOI is defined as the angle between a collimated beam incident on the optic and the surface normal (perpendicular direction) of the filter’s first surface (Figure 1). Altering the AOI from a filter’s specified nominal value will shift the peak transmission toward shorter wavelengths when increasing AOI, and toward longer wavelengths when decreasing AOI. In a simple case with a 0° AOI, this occurs because the optical path difference between reflections off the first and second surfaces of a coating layer shortens, causing interference to favor shorter wavelengths (Figure 2a and 2b). This shift toward shorter wavelengths is known as a blue shift.

Along with the shift toward shorter wavelengths, increasing AOI typically reduces transmission efficiency, creating a noticeable reduction in overall light throughput. At extreme angles deviating from the specified AOI, the entire spectral shape deforms, and the filter’s ability to perform as specified becomes highly compromised (Figure 2, top). This negatively affects overall system throughput and performance. This deterioration can be mitigated by optimizing the optical coating design (Figure 2, bottom) to block and pass specific wavelengths.

As AOI strays more from its optimal angle, the filter’s spectral profile distorts further and creates sidebands or secondary peaks, which can produce inaccurate measurements. Unwanted wavelengths may be passed and desired ones blocked, which affects data collection and accuracy. Thus, considering the AOI when constructing a system is crucial. In some cases, a custom coating design can help to avoid spectral degradation and provide optimal performance where accuracy is paramount, as in the case of virus detection.

During the COVID-19 pandemic, rapid tests were built using gold nanoparticles (AuNPs). These tests detect viral RNA or proteins using spectral shifts, with a red shift (toward longer wavelengths) occurring when nanoparticles aggregate or when the local refractive index increases due to molecular binding. A blue shift (toward shorter wavelengths) can occur if nanoparticles disperse or if the surrounding medium becomes optically less dense.

A misaligned filter in the spectroscopy device reading the samples could lead to false positives or negatives and propagate public health scares. An understanding of AOI directly aided virus detection in the early stages of the pandemic, when fear and tensions were high.

Typical AOI specifications are 0°, with a ±5° tolerance, but designs can sometimes specify other AOIs. Difficulty arises with use cases requiring larger AOI ranges. Ranges exceeding ±10° require significantly more design effort and thicker coating stacks, and they also lead to increased costs. For example, as shown in Figure 2a, a 1064-nm light source (commonly used for research) at 16° AOI will no longer pass through the filter.

When a large AOI range cannot be avoided, absorptive filters, such as color glass, may be a suitable alternative to filters with optical coatings, as their spectral performance is insensitive to the AOI and CHA of the incoming light. Absorptive filters incorporate dyes to select desired wavelengths, rather than thin-film coatings. However, thin-film interference filters typically have better spectral performance, meaning they offer higher transmission and blocking, and often at more precise wavelengths. The spectral range can be (almost) freely designed for coated filters.

For color glass, the optical absorption properties of dyes or other chemical elements dictate the optical spectra, thus rendering custom options limited. If possible, thin-film interference is preferred for its higher performance and wavelength specificity. Building on the COVID example, a virus detector that needs highly specific blocking/passing regions should opt for thin-film interference. However, if the AOI must be compromised, absorptive filters offer helpful AOI flexibility, such as in common laser beamsplitting setups.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Biophotonic probes for bio-detection and imaging

 The rapid development of biophotonics and biomedical sciences makes a high demand on photonic structures to be interfaced with biological systems that are capable of manipulating light at small scales for sensitive detection of biological signals and precise imaging of cellular structures. However, conventional photonic structures based on artificial materials (either inorganic or toxic organic) inevitably show incompatibility and invasiveness when interfacing with biological systems.

The design of biophotonic probes from the abundant natural materials, particularly biological entities such as virus, cells and tissues, with the capability of multifunctional light manipulation at target sites greatly increases the biocompatibility and minimizes the invasiveness to biological microenvironment. In this review, advances in biophotonic probes for bio-detection and imaging are reviewed. We emphatically and systematically describe biological entities-based photonic probes that offer appropriate optical properties, biocompatibility, and biodegradability with different optical functions from light generation, to light transportation and light modulation.

Three representative biophotonic probes, i.e., biological lasers, cell-based biophotonic waveguides and bio-microlenses, are reviewed with applications for bio-detection and imaging. Finally, perspectives on future opportunities and potential improvements of biophotonic probes are also provided.Sensitive detection of biological signals and precise observation of pathological changes are of great importance for the early diagnosis and treatment of infectious diseases, cancer, and other health disorders. However, owing to the low quantity of biochemical signals and complex microenvironment in biological systems, the detection of the targets of interest is challenging. Fortunately, the prosperous development of optical and photonic technologies in recent years provides many choices for optical detection and imaging, holding great promises for real-time visualization of biological signals in complex biological structures and processes.

Optical detection exploits optical responses, such as light absorption, scattering, fluorescence, and reflectance, induced by biophysical/biochemical changes for bio-identification and disease diagnosis3. Due to the inherently label-free nature, optical detection is a powerful alternative to conventional detection techniques (e.g., mass or electrochemical)With optical detection techniques, real-time signals of a wide range of biological test samples (from molecular biomarkers to pathogens and cells, and even to tissues and organs) can be obtained in a non-invasive manner with high-sensitivity and high-resolution To date, optical detection and imaging have been demonstrated to be one of the most powerful technologies for detection of biological signals and for diagnosis .

For a precise and flexible optical detection in a biological microenvironment, photonic probes with micro/nanostructures are always desirable. For this purpose, the selection of appropriate optical materials is certainly crucial, since the probing performance largely depends on their chemical and mechanical properties, optical functionalities as well as biological performances.

To date, the most commonly used materials for the assembly of versatile photonic components and photonic probes are mainly based on inorganic materials such as silica glass, or organic polymers such as polymer nanowires. Because of their excellent optical properties, such as high transparency and suitable mechanical strength, these materials have been applied for nanophotonic integrated devices in diversified fields of application. For example, optical waveguides based on silica optical fibers have been widely studied and were even used for implantations in animal bodies, particularly fiber-optic implants in the brain for optogenetic studies.

 However, the main disadvantage of these photonic components based on traditional materials is low biocompatibility and biodegradability, which greatly limit their potential in biomedical applications. High biocompatibility of a material is a fundamental requirement for in vivo applications, which demands the absence of toxicity and low health threat to the living systems29. Moreover, high biocompatibility also refers to the biofunctionalities that the implants can perform their expected functions in vivo. Additionally, biodegradability is another essential requirement, since the materials can be degraded and metabolized by the body without the need for additional operations to remove the implants.

With abundant natural biomaterials and biological entities, Mother Nature always inspire us to design photonic structures and probes to manipulate light. Indeed, living cells and microscopic organisms as well as their derivates such as DNA, proteins, silk and cellulose et al., show different capabilities to interact with light, and can further serve as different photonics devices such as waveguides, microlenses, gratings, and even lasers. These natural biomaterials and biological entities hold huge promise for creation of new photonic probes for bio-detection, imaging, and therapeutic applications.

They inherently possess excellent biological performances, including noninvasiveness, high biocompatibility, biodegradability, and resorbability. Moreover, another interesting feature of biological entities such as virus, cells and tissues is their ability to serve simultaneously as optical devices and diagnostic specimen, which facilitate further real-time detection and imaging in biocompatible microenvironments.

Therefore, instead of bio-derived materials and biomolecules (such as proteins and nucleic acids), biophotonic probes introduced in this review are mainly focused on large biological entities, such as virus, bacteria, fungi, algae, mammalian cells and tissues. By translating biological principles into man-made designs, these biophotonic probes offer a seamless interface between optical and biological worlds.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Internationally Renowned Biophotonics Researcher Secures Award to Develop New Medical Diagnostics and Treatment Tools

 Professor Stefan Andersson-Engels has been awarded €5.3 million through the SFI Research Professorship Programme, which will underpin the Biophotonics Group at Tyndall National Institute for the next five years. The funding will be used to advance the fundamental understanding of biophotonics science, the application of light-based technologies to life sciences and medicine.

This award will foster the development of new diagnostic and guidance tools to meet proven clinical needs. These will be implemented in the clinical setting of neonatology, neurosurgery, orthopaedics, and the GI tract, as well as oral cancer screening, and will be guided by 20 clinical and pre-clinical collaborators. The award aims to provide better healthcare and outcomes for patients, and to grow economic activity through the commercialisation of the resulting technologies. This will be achieved through partnerships with existing MedTech companies.

Principal Investigator at the IPIC SFI Research Centre for Photonics, Prof Andersson-Engels and his team have already created two start-up companies, one of which was in partnership with the National Cancer Centre in the Netherlands. The team has also transferred technologies to companies in the areas of cancer boundary detection and the monitoring of babies during childbirth.

The objective of Prof Andersson-Engels’ project is to use the unique properties of light, a safe, non-invasive method for humans that can accurately detect specific cells, for diagnostic purposes such as gastrointestinal diagnostics for malignancies and inflammatory bowel diseases, in-vivo oral cancer delineation and diagnosis. As light can only penetrate short distances into tissue, Prof Andersson-Engels will seek to address this challenge, and aim to facilitate light-based diagnostics and therapy deep inside the body, permitting use for many more diseases.  

Commenting on the award, Prof Andersson-Engels said: “I am delighted to be continuing our important work with the talented team across Tyndall, UCC, and IPIC. With the medical devices sector in Ireland recognised as one of the five emerging global hubs, it is an exciting time for the Biophotonics Group to forge close collaborations with companies, clinicians and research centres for the faster development and deployment of more accurate, less invasive diagnostic treatment methods for cancer and other diseases.”

Prof Andersson-Engels has an impressive track record, receiving several prizes for his research achievements, and his work on the development and commercialisation of technology has been critical to ensuring that patients will benefit from the results of scientific research. His pioneering work in the area of ALA-PDT (Photodynamic therapy) using the topical application of aminolevulinic acid (ALA), a photosensitizing agent for the treatment of non–melanoma skin cancer is currently one of the first lines of treatment at most skin cancer clinics around the world.

Welcoming the announcement, Deputy Director General of Science Foundation Ireland, Dr Ciarán Seoighe, said: “Recruiting and retaining world-leading scientific talent to Ireland is a key priority for SFI in partnership with our higher education institutions. Prof Andersson-Engels’ exceptional international track record will help to drive Ireland’s position at the forefront of photonics research. His work will contribute to improving the health and wellbeing of people by the invention and application of new technologies, as well as boosting industry engagement. We wish him every success with his research programme."

Surgical Oncologist, Head of Medical Affairs and Research, Centre for Early Cancer Detection at The Netherlands Cancer Institute, Professor Theo Ruers said: “We at The Netherlands Cancer Institute, have established a very strong and fruitful collaboration with the Biophotonics@Tyndall team over the last few years throughout the first phase of the Professorship Award. Our complementary skill sets have led to a spin-off company, multiple publications, and patents as well as collectively attracting EU and Health Holland funding. This collaboration is a win-win for both parties, and we expect the coming phase to be even more productive and impactful.”

Director of IPIC, the SFI Research Centre for Photonics, Professor Paul Townsend concluded: “This award further strengthens IPIC’s outstanding research team by providing the scientific vision and knowledge to steer existing photonic device integration towards innovative new applications in the biomedical areas. Furthermore, by continuing this world-class biophotonics research programme at IPIC and Tyndall, we can underpin strong collaborative partnerships with other Science Foundation Ireland Research Centres through projects that will present huge opportunities at a global level and again raise Ireland’s research credentials in the biomedical space.”

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Advances in biophotonic sensors: Revolutionizing medical diagnostics and research

 Biophotonic sensors and systems are optical devices developed to deliver point-of-care diagnostics for medical practitioners and health researchers. They allow researchers to detect, sense, identify, and understand biological systems at the cellular/subcellular level, allowing them to gain a deeper understanding of biological processes, conditions, and molecular changes.

Biophotonics is an emerging field demonstrating rapid growth, and optical designers and researchers are persistently developing new ways of capturing high-quality imaging, increased sensitivity detection, and more detailed analysis. Photonics technologies power medical advances like disease diagnosis, food and water safety, and drug efficacy testing. This article presents examples of biophotonic breakthroughs and how they are already making a difference across medical diagnostics and research.

Lab-on-a-chip point-of-care biophotonic sensors

Low-cost point-of-care biosensors that can deliver laboratory-quality results within minutes are making it possible to diagnose a disease early on and efficiently. This eliminates the need for expensive laboratory equipment, prolonged waiting times, and large laboratories.

For example, the lab-on-a-chip biosensors developed in response to the global COVID-19 pandemic helped combat the virus. The early spread of the disease was, in part, a result of inefficient testing protocols, and health researchers across the world worked hard to find a quick, reliable way to determine the presence of the virus.

One such way turned out to be a SARS-CoV-2 specific immunoglobulin G biophotonic sensor, which employed biofunctionalization to detect specific COVID-19 antibody selectivity. The sensors can be produced directly on the face of a single fiber optic, a single-mode fiber-28, and are sensitive enough to identify whether antibodies are present in a sample in around one minute’s time.

Optical coherence tomography (OCT) in dermatology

Previously, medical practitioners had to perform a biopsy to determine the presence of malignant tissue on the skin, but current optical coherence tomography technologies allow for a rapid, simple diagnosis without any skin excision. It can image skin to a depth of 2 mm, and resolution can be between 15 and 3 μm.

Biophotonics can also be employed during surgery to ensure full removal of problematic tissue. Nanoparticles functionalized with fluorescent dyes are applied to the skin to assemble in a particular kind of tissue. Any malignant tissue will glow when the skin is exposed to the relevant wavelengths of dye. This allows the surgeon to use epifluorescent microscopy and optical detection to decide what needs to be removed and what can be left. 

AI and biophotonic analysis

Deep learning algorithms are key for natural language processing and humanoid chatbots, and they are also central to how biophotonic data is processed. Just as machines can learn to comprehend human language, they can also learn to read the fingerprints of cells, organelles, and molecules. This enables the automation of basic diagnostics, and verification steps can be programmed into the system to ensure that nothing goes awry. 

At times, label-free identification of biological compounds will require analysis of a complex spectrum, which can be achieved by feed-forward neural networks (multilayer perceptrons, MLP) or recurrent neural networks (RNNs). These neural networks can compare test spectrums with detailed cataloged records to predict the probability of abnormal growths, disease, or the presence of other molecules. 

Deep learning algorithms can also conduct matrix multiplication containing millions of parameters, resolving complex equations that enable denoising, semantic segmentation, disease recognition, and even pseudostaining. Every day, breakthroughs in AI technologies are accelerating processing techniques and the potential of these analytical methods. 

Examples of advances in machine learning and biophotonics include AI solutions that can pull from extensive imaging data libraries to automatically detect the signs of infection in the inner ear. The AI-powered software can evaluate an OCT image of the ear captured by a portable device within half a minute. The data is then translated for diagnosis just as an expert would. 

Another example of AI in real-world applications is an intraoperative diagnosis system using stain-free, slide-free multimodal multi-photon microscopy. The data-rich images captured by biophotonic technology usually take a very long time to evaluate manually, but an AI system can generate a reliable, verifiable diagnosis in just a few minutes. 

Avantier is at the forefront of pushing the scientific envelope with advances in biophotonics. If you need a custom optical component, Avantier can manufacture exactly what you need, and a team of optical designers is on hand to help you determine what configurations will be optimally suited for your system. 

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee